You have open access to this content

Journal of Diabetes Investigation

Cover image for Vol. 5 Issue 2

Edited By: Nigishi Hotta

Impact Factor: 1.77

ISI Journal Citation Reports © Ranking: 2012: 89/122 (Endocrinology & Metabolism)

Online ISSN: 2040-1124



Author Guidelines


JDI converted to OPEN ACCESS from 2014!


All new submissions received after 24 September (US Eastern time) will be received as Open Access Articles and must be submitted via a new submission system at http://mc.manuscriptcentral.com/jdiabetesinv.

For submission of a revised manuscript which was first submitted before 23 September 2013, please submit via http://www.editorialmanager.com/jdi/

For any queries, please contact JDI Editorial Office at:
Email: JDI@wiley.com
Tel: 81 3 3830 1266
Fax 81 3 5689 7278

Author Guidelines

TABLE OF CONTENTS

1. Aims and Scope
2. Editorial Review and Acceptance
3. Manuscript Categories
4. Disclosure
5. Ethical Considerations
6. Clinical Trial Registry
7. Randomized Controlled Trials
8. Style of Manuscripts
9. Structure of Manuscripts
10. Supporting Information
11. Submission of Manuscripts
12. Editorial Office address
13. Post-Acceptance
13-1. Article Publication Charge
13-2. Open Access Agreement (OAA)
13-3. Proofs
13-4. Early View
13-5. Offprints
13-6. Wiley Author Services
13-7. Wiley Journal Online

1. AIMS AND SCOPE
Journal of Diabetes Investigation is your core diabetes journal from Asia; the official journal of the Asian Association for the Study of Diabetes (AASD). The journal publishes original research, country reports, commentaries, reviews, mini-reviews, case reports, letters, as well as editorials and news. The journal embraces clinical and experimental research in diabetes and related areas. This includes aspects of prevention, treatment, as well as molecular aspects and pathophysiology. Translational research focused on the exchange of ideas between clinicians and researchers is also welcomed. Authors and readers from all countries are welcome, and are provided with an international editorial team of experts from AASD countries and beyond.

Editor Nigishi Hotta
Frequency 6 issues per year
Impact Factor 1.77
ISSN 2040-1116 (print); 2040-1124 (online)
Journal abbreviation J Diabetes Invest
Publisher Wiley Publishing Asia Pty Ltd

2. EDITORIAL REVIEW AND ACCEPTANCE
Before peer review: Your contribution must be your own original work, which will contribute to the progress of diabetes research and treatment, and must not have been published elsewhere. Your contribution must be accompanied by your signed copyright form, a statement that your contribution has not been published elsewhere, and is not being peer reviewed elsewhere.
Acceptance: The acceptance criteria for all papers are the quality and originality of the research and its significance to our readership. Except where otherwise stated, manuscripts are peer reviewed by two anonymous reviewers, an Associate Editor and the Editor. The Editorial Board reserves the right to refuse material for publication. Final acceptance or rejection rests with the Editorial Board. Authors may present names of potential reviewers and of reviewers whom they would prefer not to review the manuscript in a covering letter. The selection of reviewers remains the Editor’s prerogative. All manuscripts should be written so that they are intelligible to the professional reader who is not a specialist in the particular field. They should be written in a clear, concise, direct style. Where contributions are judged as acceptable for publication, the Editor and the Publisher reserve the right to modify manuscripts to eliminate ambiguity and repetition and improve communication between author and reader. If extensive alterations are required, the manuscript will be returned to the author for revision.

3. MANUSCRIPT CATEGORIES

(1) ORIGINAL ARTICLE
Word limit: 4,000 words including title page, abstract but excluding references, tables and figures.
Abstract: 250 words maximum, structured (sub-headers): Aims/Introduction, Materials and Methods, Results, Conclusions.
References: No limit.
Description: Full-length reports of current re-search in either basic or clinical science. Arrange text as follows: Abstract; Introduction; Materials and Methods; Results; Discussion; Acknowledgment; References; and when relevant Supporting Information. Video is welcome as Supporting Information.

(2) SHORT REPORT
Word limit: 1,500 words including title page, abstract but excluding references, tables and figures.
Abstract: 150 words maximum, unstructured (no use of sub-headers).
References: Maximum 30.
Figures/tables: Maximum 4.
Description: New findings that will substantially and immediately affect research or clinical practice. Arrange text as follows: Abstract; Introduction; Materials and Methods; Results; Discussion; Acknowledgment; References; and when relevant Supporting Information. Video is welcome as Supporting In-formation.

(3) CASE REPORT Only cases of exceptional interest and novelty are considered. For manuscripts that do not qualify, Editors may ask authors to shorten manuscripts and rewrite as Letters to the Editor.
Word limit: 1,200 words including title page, abstract but excluding references, tables and figures. The total should be within 2 typeset pages including tables and figures.
Abstract: 150 words maximum, unstructured (no use of sub-headers).
References: Maximum 10.
Figures/tables: Maximum 4 (1a, 1b, 1c are counted as 3 figures not 1 figure).
Description: New observations of diseases, clinical findings or novel/unique treatment outcomes relevant to practitioners. Arrange text as follows: Abstract; Introduction; Case Report; Discussion; Acknowledgment; References; and when relevant Supporting Information. Video is welcome as Supporting In-formation.

(4) LETTER TO THE EDITOR
Word limit: 500 words.
Abstract: No abstract.
References: Maximum 4.
Figures/tables: Maximum 1 (Multi panel figures allowed).
Description: Letters may be submitted to the Editor on any topic of discussion; clinical observations as well as letters commenting on papers published in recent issues. Letter to the Editor are not subjected to peer-review. Submissions maybe edited for length, grammatical correctness, and journal style. Authors will be asked to approve editorial changes that alter the substance or tone of a letter or response. Letters that offer perspective on content already published in the Journal can use an arbitrary title, but a Response from authors must cite the title of the first letter: e.g. Response to [title of Letter]. This ensures that readers can track the line of discussion.

(5) COMMENTARY [BY INVITATION OR AFTER PROPOSAL OUTLINE]
Word limit: 1,500 words excluding references, tables and figures.
Title: 115 characters maximum including spaces.
References: Maximum 5.
Figures/tables: Maximum 1-2.
Description: Commentaries discuss a paper published in a specific issue and should set the problems addressed by the paper in the wider context of the field.

(6) MINI REVIEW [BY INVITATION OR AFTER PROPOSAL OUTLINE]
Word limit: 3,000 words including abstract but excluding references, tables and figures.
Abstract: 250 words maximum, structured or unstructured.
References: Maximum 50.
Figures/tables: Minimum 1 image or figure.
Description: Mini reviews are comprehensive analyses of specific topics. They are submit-ted upon invitation by the Editor. Proposals for reviews may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Both solicited and unsolicited review articles will undergo peer review prior to acceptance.

(7) REVIEW [BY INVITATION OR AFTER PROPOSAL OUTLINE]
Word limit: 5,000 words including abstract but excluding references, tables and figures.
Abstract: 250 words maximum, structured or unstructured.
References: No maximum.
Figures/tables: Minimum 2 images or figures.
Description: Reviews are comprehensive analyses of specific topics. They are submitted upon invitation by the Editor. Proposals for reviews may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Both solicited and unsolicited review articles will undergo peer review prior to acceptance.

(8) EDITORIAL [BY INVITATION OR AFTER PROPOSAL OUTLINE]
Word Limit: 1,600 words.
Abstract: No abstract.
References: Maximum 5.
Description: Proposals for Editorials may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration.

(9) GUIDELINE

Word limit: 5,000 words, or to be determined in consultation with Editors if longer.
Abstract: 250 words maximum, unstructured (no use of sub-headers).
References: No maximum.
Description: Guidelines designed to help clinicians make decisions about appropriate diagnosis and treatment for specific circumstances.

(10) SPECIAL REPORT [BY INVITATION OR AFTER PROPOSAL OUTLINE]
Word limit: To be determined in consultation with Editors.
Preface: 250 words maximum, unstructured (no use of sub-headers).
References: No limit.
Description: Country, meeting or special subject reports. Proposals for these articles may be submitted; however, in this case authors should only send an outline of the proposed paper for initial consideration. Both solicited and unsolicited articles will undergo peer review prior to acceptance.

(11) CLINICAL TRIAL
Word limit: 4,000 words, including title page, abstract but excluding references, tables and figures.
Abstract: 250 words maximum, structured (sub-headers): Introduction, Materials and Methods, Results, Discussion.
References: No limit.
Figures/tables: Maximum 5 (1a, 1b, 1c are counted as 3 figures not 1 figure). A flow diagram should be included.
Description: Full-length reports of preventive, therapeutic, or diagnostic intervention, and the follow up to determine the effect of the intervention. Arrange text as follows: Abstract; Introduction; Materials and Methods; Results; Discussion; Acknowledgment; References; and when relevant Supporting Information. If needed, authors may send an outline of the proposed paper for initial consideration. Trials should adhere to sections 6 and 7 of this author guide.

4. DISCLOSURE
Author should declare any financial support or relationships that may pose conflict of interest in the Covering Letter and Acknowledgments.

5. ETHICAL CONSIDERATIONS
Authors must state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki (as revised in Edinburgh 2000), available at: http://www.wma.net/e/policy/b3.htm. The journal retains the right to reject any manuscript on the basis of unethical conduct of either human or animal studies. All investigations on human subjects must include a statement that the subject gave informed consent. Patient anonymity should be preserved. Photographs need to be cropped sufficiently to prevent human subjects being recognized (or an eye bar should be used).
In general, submission of a case report should be accompanied by the written consent of the subject (or parent/guardian) before publication; this is particularly important where photographs are to be used or in cases where the unique nature of the incident reported makes it possible for the patient to be identified. While the Editors recognize that it might not always be possible or appropriate to seek such consent, the onus will be on the authors to demonstrate that this exception applies in their case.
Any experiments involving animals must be demonstrated to be ethically acceptable and where relevant conform to national guidelines for animal usage in research.

6. CLINICAL TRIAL REGISTRY
We strongly recommend, as a condition of consideration for publication, registration in a public trials registry. Trials register at or before the onset of patient enrollment. This policy applies to any clinical trial starting enrollment after January 1, 2006. For trials that began enrollment before this date, we request registration by April 1, 2006, before considering the trial for publication. We define a clinical trial as any research project that prospectively assigns human subjects to intervention or comparison groups to study the cause-and-effect relationship between a medical intervention and a health outcome. Studies designed for other purposes,
such as to study pharmacokinetics or major toxicity (e.g., phase 1 trials) are exempt. We do not advocate one particular registry, but registration are with a registry that meets the following minimum criteria: (1) accessible to the public at no charge; (2) searchable by standard, electronic (Internet-based) methods; (3) open to all prospective registrants free of charge or at minimal cost; (4) validates registered information; (5) identifies trials with a unique number; and (6) includes information on the investigator(s), research question or hypothesis, methodology, intervention and comparisons, eligibility criteria, primary and secondary outcomes
measured, date of registration, anticipated or actual start date, anticipated or actual date of last follow-up, target number of subjects, status (anticipated, ongoing or closed) and funding source(s). Registries that currently meet these criteria include: (1) the registry sponsored by the United States National Library of Medicine (http://www.clinicaltrials.gov); (2) the International Standard Randomized Controlled Trial Number Registry (http://www.controlled-trials.com); (3) the Australian Clinical Trials Registry (http://www.actr.org.au); (4) the Chinese Clinical Trials Register (http://www.chictr.org); and (5) the Clinical Trials Registry - India (http://www.ctri.in); (6) University hospital Medical Information Network (UMIN) (http://www.umin.ac.jp/ctr/); (7) the Clinical Study Results Database (http://clinicalstudyresults.org/).

7. RANDOMIZED CONTROLLED TRIALS
Reporting of randomized controlled trials should follow the guidelines of The CONSORT Statement: http://www.consort-statement.org

8. STYLE OF MANUSCRIPTS
Manuscripts must follow the style detailed in the International Committee of Medical Journal Editors’ revised ‘Uniform Requirements for Manuscripts Submitted to Biomedical Journals: Writing and Editing for Biomedical Publication’, as presented at: http://www.ICMJE.org/

Spelling The Journal uses US spelling and authors should therefore follow the latest edition of the Merriam–Webster’s Collegiate Dictionary. Foreign names and terms, such as names of chemicals should be written in the original language. Proper nouns and German nouns should be capitalized. Units All measurements must be given in SI or SI-derived units. For more information about SI units, please go to the Bureau International des Poidset Mesures (BIPM) website at: http://www.bipm.org/

Abbreviations Must be used sparingly – only where they ease the reader’s task by reducing repetition of long, technical terms. Initially use the word in full, followed by the abbreviation in parentheses. Thereafter use the abbreviation only.

Trade names Drugs should be referred to by their generic names. If proprietary drugs have been used in the study, refer to these by their generic name, mentioning the proprietary name, and the name and location of the manufacturer, in parentheses.

9. STRUCTURE OF MANUSCRIPTS
The length of manuscripts must adhere to the specifications under the section Manuscript Categories.

Manuscripts should be presented in the following order: (i) title page, (ii) abstract and keywords, (iii) text, (iv) acknowledgments including disclosure, (v) references, (vi) supporting information, (vii) figure legends, (viii) tables (each table complete with title and footnotes) and (ix) figures. Footnotes to the text are not allowed and any such material should be incorporated into the text as parenthetical matter.

TITLE PAGE The title page should contain (i) manuscript category, (ii) the title of the paper, (iii) the full names of the authors, (iv) the names and addresses of the institutions at which the work was carried out, (v) the full postal and email address, plus facsimile and telephone numbers, of the author to whom correspondence about the manuscript should be sent (vi) short running title, and (vii) a word count. The present address of any author, if different from that where the work was carried out, should be supplied in a footnote. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author's contribution to the paper is to be quantified. The title should be short, informative and contain the major key words so that readers and in particular online users will discover the article easily in online search. Do not use abbreviations in the title. A short running title (less than 40 characters including spaces) should also be provided. The running title is the short title in the upper right-hand corner of articles to help article search.

ABSTRACT AND KEYWORDS
The length of abstracts must adhere to the specifications under the section Manuscript Categories. Please note that the require-ments differ between manuscript types. The abstract should not contain abbreviations or references. Up to three keywords, for the purposes of indexing and peer review, should be supplied below the abstract, in alphabetical order, and should be taken from those recommended by the US National Library of Medicine’s Medical Subject Headings (MeSH): http://www.nlm.nih.gov/mesh/meshhome.html

TEXT
Please note that the requirements differ between manuscript types. Please refer to MANUSCRIPT CATEGORIES for individual requirements.

ACKNOWLEDGMENTS
The source of financial grants and other funding must be acknowledged, including a frank declaration of the authors’ industrial links and affiliations. The contribution of col-leagues or institutions should also be acknowledged. Thanks to anonymous reviewers are not appropriate.

REFERENCES
The Vancouver system of referencing should be used (examples are given below). In the text, references should be cited using superscript Arabic numerals in the order in which they appear. If cited in tables or figure legends, number according to the first identification of the table or figure in the text. In the reference list up to 3 authors; when four or more, list the first three followed by et al. Do not use ibid. or op cit. Reference to unpublished data and personal communications should not appear in the list but should be cited in the text only (e.g. Smith A, 2000, unpublished data). All citations mentioned in the text, tables or figures must be listed in the reference list. Names of journals should be abbreviated in the style used in Index Medicus. Authors are responsible for the accuracy of the references.

Journal articles: Sculpher MJ, Buxton MJ, Fer-guson BA et al. A relative cost-effectiveness analysis of different methods of screening for diabetic retinopathy. Diabet Med 1991; 8: 644-650.
Journal articles published ahead of issue (print or online): Benz PJ, Soll J, Bölter B. Protein transport in organelles: The composition, function and regulation of the Tic complex in chloroplast protein import. FEBS Journal, 2009. doi: 10.1111/j.1742-4658.2009.06874.x
Books: Pickup J, Williams G. Textbook of Diabetes, 2nd edn. Oxford: Blackwell Science 1997.
Chapters in edited books: Russell, W.E. & Van Wyk, J.J. Peptide growth factor. In Endocrinology (ed. L. J. De Groot). W. B. Saunders, Philadelphia, 1989: 2504-2524.

TABLES
Tables should be self-contained and complement, but not duplicate, information contained in the text. Number tables consecutively in the text in Arabic numerals. Type tables on a separate page with the legend above. Legends should be concise but comprehensive – the table, legend and footnotes must be understandable without reference to the text. Vertical lines should not be used to separate columns. Column headings should be brief, with units of measurement in parentheses; all abbreviations must be defined in footnotes. Footnote symbols: †, ‡, §, ¶, should be used (in that order) and *, **, *** should be reserved for P-values. Statistical measures such as SD or SEM should be identified in the headings. Tables should be submitted in Microsoft Word or Excel. Image files and groupings of text boxes should be avoided. If tables have been reproduced from another source, a letter from the copyright holder (usually the Publisher), stating authorization to reproduce the material, must be attached to the covering letter.

FIGURES
All illustrations (line drawings and photographs) are classified as figures. Figures should be cited in consecutive order in the text. Magnifications should be indicated using a scale bar on the illustration. If figures have been reproduced from another source, a letter from the copyright holder (usually the Publisher), stating authorization to reproduce the material, must be attached to the covering letter.

Size: Figures sizes to fit within the column (82 mm), intermediate (118 mm) or the full text width (173 mm).

Resolution: Figures must be supplied as high resolution saved as .eps or .tif. Halftone figures 300 dpi (dots per inch), Color figures 300 dpi saved as CMYK, figures containing text 400 dpi, Line figures 1000 dpi.

Color figures: Files should be set up as CMYK (cyan, magenta, yellow, black) and not as RGB (red, green, blue) so that colors as they appear on screen will be a closer representation of how they will print in the Journal.

Line figures: Must be sharp, black and white graphs or diagrams, drawn professionally or with a computer graphics package.

Text sizing in figures: Lettering must be included and should be sized to be no larger than the journal text or 8 point (Should be readable after reduction – avoid large type or thick lines).
Line Width: Between 0.5 and 1 point.

Figure legends
: Type figure legends on a separate page. Legends should be concise but comprehensive – the figure and its legend must be understandable without reference to the text. Include definitions of any symbols used and define/explain all abbreviations and units of measurement. More help on preparation of illustrations can be found at: http://authorservices.wiley.com/bauthor/illustration.asp/

EQUATIONS
Equations should be numbered sequentially with Arabic numerals; these should be ranged right in parentheses. All variables should appear in italics. Use the simplest possible form for all mathematical symbols.

10. SUPPORTING INFORMATION
Supporting Information is provided by the authors to support the content of an article but they are not integral to that article. They are hosted via a link on Wiley Online Library but do not appear in the print version of the article. Supporting Information must be submitted together with the article for review; they should not be added at a later stage. They can be in the form of tables, figures, appendices and even video footage. Reference to Supporting Information in the main body of the article is allowed. However, it should be noted that excessive reference to a piece of Supporting Information may indicate that it would be better suited as a proper reference or fully included figure/table. The materials will be published as they are supplied and will not be checked or typeset in any way. All Supporting Information files should come with a legend, listed at the end of the main article. Each figure and table file should not be larger than 5MB, although video files may be larger.
Prior to submission, please check the guidelines: http://authorservices.wiley.com/bauthor/suppinfo.asp


11. SUBMISSION OF MANUSCRIPTS
As of 24 September 2013, JDI receives all the new submissions as open access articles. Manuscripts should be submitted online at http://mc.manuscriptcentral.com/jdiabetesinv. Authors must supply an email address as all correspondence will be by email.

General
All articles submitted to the Journal must comply with these instructions. Failure to do so will result in return of the manuscript and possible delay in publication.
• Submissions must be double-spaced.
• All margins should be at least 30 mm.
• All pages should be numbered consecutively in the top right-hand corner, beginning with the title page.
• Do not use 'Enter' at the end of lines within a paragraph.
• Turn the hyphenation option off; include only those hyphens that are essential to the meaning.
• Specify any special characters used to represent non-keyboard characters.
• Take care not to use l (ell) for 1 (one), O (capital o) for 0 (zero) or ß (German esszett) for Greek beta
• Use a tab, not spaces, to separate data points in tables. If you use a table editor function, ensure that each data point is contained within a unique cell (i.e. do not use carriage returns within cells).
• Each figure should be supplied as a separate file, with the figure number incorporated in the file name. For submission, low-resolution figures saved as .jpg or .bmp files should be uploaded, for ease of transmission during the review process. Upon acceptance of the article, high-resolution figures (at least 300 d.p.i.) saved as .eps or .tif files should be uploaded. Digital images supplied only as low-resolution files cannot be used for publication.
Covering letter
Manuscripts are accepted for publication in the Journal on the understanding that the content has not been published or submitted for publication elsewhere except as a brief abstract in the proceedings of a scientific meeting or symposium. This must be stated in the covering letter.

The covering letter must also contain an acknowledgment that all authors have contributed significantly, and that all authors are in agreement with the content of the manuscript. In keeping with the latest guidelines of the International Committee of Medical Journal Editors, each author's contribution to the paper is to be quantified.
Names of potential reviewers and of reviewers whom they would prefer not to review the manuscript will be mentioned if you have any.

Authors must also state that the protocol for the research project has been approved by a suitably constituted Ethics Committee of the institution within which the work was undertaken and that it conforms to the provisions of the Declaration of Helsinki in 1995 (as revised in Edinburgh 2000). All investigations on human subjects must include a statement that the subject gave informed consent and patient anonymity should be preserved. Authors should declare any financial support or relationships that may pose conflict of interest.

12. EDITORIAL OFFICE ADDRESS

JDI Editorial office
c/o Wiley Japan
4F, Frontier Koishikawa Bldg.
1-28-1 Koishikawa, Bunkyo-ku
Tokyo 112-0002
Japan
E-mail: jdi@wiley.com
Tel: 81 3 3830 1220
Fax: 81 3 5689 7278

- - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - - -

13. POST-ACCEPTANCE

13-1. ARTICLE PUBLICATION CHARGE
Manuscripts submitted after 24 September 2013 and accepted for publication will be published as open access articles, immediately free to read, download and share. You or your funder will be required to pay an Article Publication Charge on acceptance.

Invited articles are free of any publication charges.

We will waive or discount charges for corresponding authors covered by the Research4Life Initiative (see the Wiley Open Access Waiver Country List).
Authors of articles should be aware that publication of their manuscript cannot proceed without payment of the article publication charge. Authors are therefore requested to pay the article publication charge promptly i.e. within two weeks of receipt of the invoice.

Authors who receive funding from an agency or institution with a Wiley Open Access Account do not pay directly. The charge is paid by the institution or funder. Authors whose institutions have paid the Wiley Open Access partner fee are eligible for a discount on the publication charge and on acceptance a discounted fee is payable by the author. More details are available here. Please refer to the article publication charges (http://onlinelibrary.wiley.com/journal/10.1111/(ISSN)2040-1124/homepage/article_publication_charges.htm) for more details.

13-2. OPEN ACCESS AGREEMENT (OAA)
If your paper is accepted, the author whom you identify as being the corresponding author for the paper the author will receive an email prompting them to login into Author Services; where via the Wiley Author Licensing Service (WALS) they will be able to complete the license agreement on behalf of all authors on the paper.The corresponding author will be presented with the option to sign an open access agreement (on behalf of all co-authors) to make the paper available under the terms of either the Creative Commons Attribution Non-Commercial (CC-BY-NC) license or the Creative Commons Attribution-Non-Commercial-NoDerivs (CC-BY-NC-ND) license. From 1st April 2013, RCUK or Wellcome trust funded authors will be directed to sign the open access agreement under the terms of the Creative Commons Attribution (CC-BY) license in order to be funder compliant. For more information on the terms and conditions of these licenses please visit: http://www.wileyopenaccess.com/details/content/12f25db4c87/Copyright--License.html

13-3. PROOFS
It is essential that submitting authors supply an email address to which proofs can be emailed. Notification of the URL from where to download a Portable Document Format (PDF) typeset proof will be sent to the submitting author via email as a final check of the layout, tables and figures. (Note that the corresponding author will only receive the PDF typeset proof if he is the submitting author.) Alterations (other than the essential correction of errors) and addition/deletion of co-authors are unacceptable at PDF stage. Further instructions will be sent with the proof. The submitting author will be given a 48 hour turn-around time to return proof corrections. Submitting authors who will not be available to check their proofs should appoint someone to proofread their article. If the proof is not returned by the appointed date, it may be signed off on by the Editor or held over to the next issue.

13-4. EARLY VIEW
JDI is covered by Wiley Blackwell’s Early View service. Early View articles are complete full-text articles published online in advance of their publication in a printed issue. Articles are therefore available as soon as they are ready, rather than having to wait for the next scheduled print issue. Early View articles are complete and final. They have been fully reviewed, revised and edited for publication, and the authors’ final corrections have been incorporated. Because they are in final form, no changes can be made after online publication. The nature of Early View articles means that they do not yet have volume, issue or page numbers, so Early View articles cannot be cited in the traditional way. They are therefore given a Digital Object Identifier (DOI), which allows the article to be cited and tracked before it is allocated to an issue. After print publication, the DOI remains valid and can continue to be used to cite and access the article. More information about DOIs can be found at http://www.doi.org/faq.html

13-5. OFFPRINTS
A minimum of 50 offprints will be provided upon request, at the author's expense. These paper offprints may be ordered online. Please visit http://offprint.cosprinters.com/, fill in the necessary details and ensure that you type information in all of the required fields. If you have queries about offprints please email offprint@cosprinters.com

13-6. WILEY AUTHOR SERVICES
Authors of accepted papers will receive an invitation to sign up to Author Services that will enable them to track accepted articles through the production process. Authors can check the status of their articles online and choose to receive automated emails at key stages of production so they do not need to contact the production editor to check on progress. Visit Author Services (http:/authorservices.wiley.com/bauthor/author.asp) for more details on online production tracking. This site also includes useful information such as copyright matters, ethics, electronic artwork guidelines, ways to optimize articles for search engines, FAQs and tips on article preparation, submission and more.

13-7. WILEY JOURNAL ONLINE
Visit the JDI home page at http://wileyonlinelibrary.com/journal/jdi for more information.


SEARCH

SEARCH BY CITATION